HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SXTC
China SXT Pharmaceuticals, Inc.
There isn't enough reported data to score SXTC yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SXTC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
SXTC's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SXTC PE Valuation
SXTC has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SXTC Forward outlook
There aren't enough analyst estimates for SXTC to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over SXTC in the latest year-over-year earnings comparison.
SXTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2019 | $1,440,000,000.00 | +6592401% |
SXTC has swung to a loss: it lost $258,864,000.00 per share over the past year, after a profit the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SXTC in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SXTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $511.5K | -44% |
| Q3 2025 | $626.6K | -24% |
| Q1 2025 | $911.4K | -7.8% |
| Q3 2024 | $829.5K | -12% |
| Q1 2024 | $988.9K | +30% |
| Q3 2023 | $939.6K | -22% |
| Q1 2023 | $763.4K | -52% |
| Q3 2022 | $1.2M | +18% |
SXTC's revenue has slid since its 2019 peak: $511,482 last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -153% | -844 points |
| Q3 2025 | -1012% | -17 points |
| Q1 2025 | -224% | +360 points |
| Q3 2024 | -77% | +18 points |
| Q1 2024 | 691% | +837 points |
| Q3 2023 | -995% | -714 points |
| Q1 2023 | -584% | -217 points |
| Q3 2022 | -95% | -125 points |
SXTC's operating margin was −153% last quarter, down 844 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
SXTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2022 | -$569.2K | -$235.8K |
| Q1 2022 | $540.8K | +$1.6M |
| Q3 2021 | -$333.5K | +$5K |
| Q1 2021 | -$1.1M | -136% |
| Q3 2020 | -$338.4K | +$1.8M |
| Q1 2020 | $3M | +$3.2M |
| Q1 2019 | -$296.6K | -126% |
| Q1 2018 | $1.2M | +2543% |
SXTC has the edge over HIMS in the latest year-over-year cash flow comparison.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SXTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -85% | -88 shares |
| Quarter | Spent |
|---|---|
| Q1 2018 | — |
| Q4 2017 | — |
| Q3 2017 | — |
| Q2 2017 | — |
| Q1 2017 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SXTC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -2.8x | Net Cash |
| Q3 2020 | -24.2x | Net Cash |
| Q1 2019 | -4.7x | Net Cash |
| Q1 2018 | -0.1x | Net Cash |
| Q4 2017 | 0.1x | Very low |
SXTC has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SXTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.3 | Oversold |
| Stochastic | 0.0 | Oversold |
SXTC's weekly RSI is 26 (oversold) and its Stochastic is 0 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SXTC PE vs Healthcare Sector
| Metric | SXTC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SXTC has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SXTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $66.5 | 96% below |
| 20 week MA | $3,168.2 | 100% below |
| 50 week MA | $201,104.1 | 100% below |
| 100 week MA | $1,416,712.0 | 100% below |
| 200 week MA | $16,515,528.3 | 100% below |
SXTC is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over SXTC on returns for 2026, with the stronger performance.
SXTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14,687,808,000.0 | $6,504,960,000.0 | -56% |
| 2021 | $6,504,960,000.0 | $2,753,856,000.0 | -58% |
| 2022 | $2,753,856,000.0 | $124,800,000.0 | -95% |
| 2023 | $124,800,000.0 | $38,112,000.0 | -69% |
| 2024 | $38,112,000.0 | $4,012,800.0 | -89% |
| 2025 | $4,012,800.0 | $1,812,000.0 | -55% |
| 2026 YTD | $1,812,000.0 | $2.73 | -100% |
SXTC has finished every year since 2020 lower, and it's down 100% so far in 2026.